A 67-Year-Old Woman With Differentiated Thyroid Cancer - Episode 5
Lori Wirth, MD: In terms of patient selection on the SELECT trial, we saw patients with iodine-refractory DTC [differentiated thyroid cancer] of all different subtypes enrolled in the trial. Patients with papillary thyroid cancer, follicular thyroid cancer, Hürthle cell carcinoma, and also poorly differentiated thyroid cancer were all enrolled in the SELECT trial.
When we took a look at a subgroup analysis to see if all patients in the subgroups benefited, or only some of the patients in some of the subgroups, what we found was that there was good activity in all the subtypes of thyroid cancers enrolled. I think we’re seeing that lenvatinib has activity in all subtypes, not just papillary thyroid cancer but also follicular, Hürthle cell, and even poorly differentiated thyroid cancer.
One thing patients often ask me once they’re on lenvatinib and they’ve had a response is, “How long am I going to be on lenvatinib?” We now have data that can help answer that question. Andrew Gianoukakis did an analysis of the SELECT trial. What was found was that when patients do respond, the median duration of response is more than 30 months. That piece of data is very helpful in telling patients, in answering that really important question for patients.
Transcript edited for clarity.
Case: A 67-Year-Old Woman With Differentiated Thyroid Cancer
Treatment and Follow-Up